Latest news with #BETR-001
Yahoo
22-05-2025
- Business
- Yahoo
BetterLife Provides Comments on CEO's Share Position Ownership and Recent BCSC Press Release
VANCOUVER, British Columbia, May 22, 2025 (GLOBE NEWSWIRE) -- BetterLife Pharma Inc. ('BetterLife' or the 'Company') (CSE: BETR / OTCQB : BETRF / FRA: NPAU), an emerging biotech company focused on the development of BETR-001, a non-hallucinogenic neuroplastogen in the treatment of psychiatric and neurological disorders, is issuing the following press release in response to British Columbia Securities Commission's ('BCSC') May 21, 2025 news release. BetterLife announced on July 16, 2024, that it had amended its past Management Information Circulars ('MIC') to correct disclosures of beneficial ownership by its Chief Executive Officer, Dr. Ahmad Doroudian. The July 16, 2024, press release corrected Mr. Doroudian's beneficial ownership as follows: Dates of MIC andRelated RecordDates Section in MIC Amount of BeneficialOwnership andPercentage of Class (ifapplicable) asDisclosed in MIC Amended Amount ofBeneficial Ownershipand Percentage ofClass (if applicable) February 28 andFebruary 10, 2023 Proposal No. 2 – Election ofDirectors 5,506,367 common 5,863,786 common November 23 andNovember 5, 2021 Proposal No. 2 – Election ofDirectors 5,155,162 common 5,529,887 common November 20 andNovember 9, 2020 Voting Securities andPrincipal Holders of VotingSecurities 5,155,162 common13.9% 5,251,637 common14.2% February 15 andFebruary 13, 2019 Principal Stockholders andSecurity Ownership ofManagement 9,161,929 common9.455% 21,330,518 common22.01% Since early 2023, through direct investment of $675,000 and settlement of his annual salary with BetterLife shares, Dr. Doroudian has increased his ownership from approximately 5.8 million shares to 16 million shares. 'I am disappointed by the recent BCSC penalty, but extremely proud of my contributions to BetterLife and the Company's achievements thus far. I am truly excited about the prospects of BetterLife and its lead asset BETR-001,' said Dr. Doroudian. About BetterLife Pharma BetterLife Pharma Inc. is an emerging biotechnology company primarily focused on developing and commercializing two compounds, BETR-001 and BETR-002, to treat neuro-psychiatric and neurological disorders. BETR-001, which is in preclinical and IND-enabling studies, is a non-hallucinogenic neuroplastogen. BETR-001 is a non-controlled substance. BETR-001 will be developed for the treatment of various psychiatric and neurological disorders. BETR-001 pending patent, for composition and method of use, covers treatment of major depressive disorder, anxiety disorder and neuropathic pain and other neuro-psychiatric and neurological disorders. BETR-002, which is in preclinical and IND-enabling studies, is based on honokiol, the active anxiolytic ingredient of magnolia bark. BetterLife's pending method of use and formulations patent covers treatment of anxiety-related disorders including benzodiazepine dependency. BetterLife also owns a drug candidate for the treatment of viral infections and is in the process of seeking strategic alternatives for further development. For further information, please visit BetterLife Pharma. ContactDavid Melles, Investor Relations Manager Email: 1-778-887-1928 Cautionary Note Regarding Forward-Looking Statements No securities exchange has reviewed nor accepts responsibility for the adequacy or accuracy of the content of this news release. This news release contains forward-looking statements relating to product development, licensing, commercialization and regulatory compliance issues and other statements that are not historical facts. Forward-looking statements are often identified by terms such as 'will', 'may', 'should', 'anticipate', 'expects' and similar expressions. All statements other than statements of historical fact, included in this release are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ materially from the Company's expectations include the failure to satisfy the conditions of the relevant securities exchange(s) and other risks detailed from time to time in the filings made by the Company with securities regulations. The reader is cautioned that assumptions used in the preparation of any forward-looking information may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks, uncertainties, and other factors, many of which are beyond the control of the Company. The reader is cautioned not to place undue reliance on any forward-looking information. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made as of the date of this news release and the Company will update or revise publicly any of the included forward-looking statements as expressly required by applicable in to access your portfolio
Ottawa Citizen
14-05-2025
- Health
- Ottawa Citizen
BetterLife Pharma Provides Scientific Update of Mechanism of Action of BETR-001 in Treatment of Psychiatric Disorders
Article content VANCOUVER, British Columbia, May 14, 2025 (GLOBE NEWSWIRE) — BetterLife Pharma Inc. ('BetterLife' or the 'Company') (CSE: BETR / OTCQB : BETRF / FRA: NPAU), an emerging biotech company focused on the development of BETR-001, a non-hallucinogenic neuroplastogen in the treatment of psychiatric and neurological disorders, recently presented a scientific update at Bloom Burton Conference on May 5, 2025 in Toronto, Canada. Article content Article content Article content BetterLife reported that its proprietary compound, BETR-001, is showing very promising preclinical data of its breakthrough ability to provide therapeutic effect in depression/anxiety animal models. Current methods of treating depression/anxiety primarily focus on increasing the level of one of the three neurotransmitters: serotonin, norepinephrine and/or dopamine in the brain. Each neurotransmitter has different receptor targets, and each receptor performs different functions. Current treatments are usually reuptake inhibitors such as SSRIs (selective serotonin reuptake inhibitors) and by increasing the amount of a neurotransmitter, all its receptors are activated. What is needed are new treatments that activate the neuroreceptors themselves, and more importantly, only selective subsets of these receptors. Article content The therapeutic effects of BETR-001 seen in preclinical models are primarily driven by its activation (agonism) of serotonin's 5HT2A receptor. Not only does BETR-001 activate the 5HT2A receptor, which plays a key role in depression/anxiety, this activation is via a mechanism that allows for a highly efficacious therapeutic effect without hallucinogenic side effects. This stands in contrast to other potent 5HT2A activators, such as LSD, psilocybin and other psychedelics. BetterLife has reported on the details of BETR-001 activation of the 5HT2A receptor previously (Lewis et al., Cell Reports, 2023). Recently studies have shown that the activation of the 5HT2A receptor above 70% leads to hallucination (Wallach et al., Nature Communications, 2023). Ideally, a therapeutic agent should activate 5HT2A but stay below the 70% threshold. BETR-001 fulfills this parameter perfectly: activating 5HT2A maximally to 60%, unlike LSD, which activates 5HT2A to near 90%. This is shown in our 5HT2A receptor activation data below, where the X-axis is an increasing amount of the drug, and the Y axis is the percentage activation of the 5HT2A receptor. The drugs tested are 5-HT (the parent serotonin), LSD and BETR-001. Article content Article content BetterLife believes that BETR-001's novel mechanism of action provides a new paradigm for treatment of psychiatric disorders such as depression, anxiety and PTSD. It activates the 5HT2A receptor partially but stays below the hallucination threshold. In addition, unlike LSD, psilocybin, MDMA and other such agents BETR-001 is not an activator of the 5HT2B receptor. Activation of 5HT2B has been linked to cardiac safety. The neuroreceptor selectivity of BETR-001 in this regard is another of its key advantages over other competitor agents. An additional benefit of BETR-001 is that repeated dosing does not induce tolerance, unlike classic agents like LSD. This allows daily administration if needed. Furthermore, the lack of hallucinations with BETR-001 means it is a non-controlled substance and patient self-administration at home is possible. Finally, an overarching property of BETR-001 is that it is a very potent neuroplastogen.
Globe and Mail
18-03-2025
- Business
- Globe and Mail
CS Diagnostics (OTCQB: CSDX) CS-Protect Hydrogel FDA Approval on Fasttrack – GNPX, BON, SES, BETRF – Stocks to Watch Now!
CS Diagnostics (OTCQB: CSDX) CS-Protect Hydrogel FDA Approval on Fast Track – GNPX, BON, SES, BETR.C – Stocks to Watch CS Diagnostics Corp. (OTCQB: CSDX) has engaged Lachman Consultants Inc. to support FDA approval for its CS-Protect Hydrogel, an innovative organ spacer medical device designed to enhance radiation therapy outcomes. Approval is expected within 3–4 months, with U.S. production targeted for early 2026. CS-Protect Hydrogel offers a breakthrough in cancer radiology, eliminating contamination risks and ensuring precise treatment application. Lachman Consultants, a leader in regulatory compliance since 1978, will assist in streamlining the approval process. Vice President Mohammad EsSayed noted that Boston Scientific previously acquired a similar product for $500 million, underscoring the strong market potential. As an OTCQB-listed company, CS Diagnostics Corp. offers a high-growth investment opportunity in medical device innovation. Other Developing Growth Stocks to Watch in 2025 Genprex, Inc. (NASDAQ: GNPX) is advancing its diabetes gene therapy program through a strategic collaboration with a CDMO to develop a next-generation non-viral lipid nanoparticle delivery system. A leader in gene therapy for cancer and diabetes, Genprex utilizes its Oncoprex® Delivery System for targeted tumor suppression and its GPX-002 therapy to restore insulin production. The company's lead candidate, Reqorsa® Gene Therapy, is in clinical trials for lung cancer, with FDA Fast Track and Orphan Drug Designations, reinforcing its mission to deliver breakthrough treatments for underserved patients. Bon Natural Life (Nasdaq: BON) Raises $12M in Best Efforts Offering of 8.33 million Class A ordinary shares (or pre-funded warrants), along with Series A and B Warrants at $1.44 and $2.16 per share, respectively. The Warrants are immediately exercisable, with a three-year expiration. Proceeds will fund sales expansion, R&D, production growth, and working capital. The offering is set to close around March 18, 2025, pending customary conditions. SES AI Corp (NYSE: SES) Advances Lithium-Metal Battery Technology for EVs and eVTOL and is pioneering high-performance Lithium-Metal (Li-Metal) rechargeable battery technologies for electric vehicles (EVs), eVTOL aircraft, and other applications. As an integrated Li-Metal battery manufacturer, SES develops materials, cells, modules, AI-powered safety algorithms, and recycling solutions, positioning itself at the forefront of next-generation energy storage innovation. BetterLife Pharma (CSE: BETR) (OTCQB: BETRF) Secures Key Patent for BETR-001. BetterLife Pharma Inc. has been granted a composition of matter patent (US2023/0219955) for BETR-001, a non-hallucinogenic LSD derivative in development for major depressive disorder, anxiety, and neuropathic pain, extending protection until 2042. With multiple patents covering its synthesis and use, BETR-001 eliminates regulatory hurdles as an uncontrolled substance. The company is also developing BETR-002, a honokiol-based therapy for anxiety disorders, while seeking strategic alternatives for its antiviral drug candidate. As CS Diagnostics Corp. (OTCQB: CSDX) fast-tracks its FDA approval, Genprex (NASDAQ: GNPX) advances gene therapy, Bon Natural Life (Nasdaq: BON) secures funding, SES AI (NYSE: SES) accelerates battery innovation, and BetterLife Pharma (CSE: BETR) (OTCQB: BETRF) strengthens its IP portfolio, these companies are making significant strides in their respective industries, presenting potential investment opportunities for market watchers. Disclaimers: The Private Securities Litigation Reform Act of 1995 provides investors with a safe harbor with regard to forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, assumptions, objectives, goals, and assumptions about future events or performance are not statements of historical fact and may be forward looking statements. Forward looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties that could cause actual results or events to differ materially from those presently anticipated. Forward looking statements in this action may be identified through use of words such as projects, foresee, expects, will, anticipates, estimates, believes, understands, or that by statements, indicating certain actions & quotes; may, could or might occur Understand there is no guarantee past performance is indicative of future results. Investing in micro-cap or growth securities is highly speculative and carries an extremely high degree of risk. It is possible that an investor's investment may be lost or due to the speculative nature of the companies profiled. TheStreetReports (TSR) is responsible for the production and distribution of this content."TSR" is not operated by a licensed broker, a dealer, or a registered investment advisor. It should be expressly understood that under no circumstances does any information published herein represent a recommendation to buy or sell a security. "TSR" authors, contributors, or its agents, may be compensated for preparing research, video graphics, podcasts and editorial content. "TSR" has not been compensated to produce content related to "Any Companies" appearing herein. As part of that content, readers, subscribers, and everyone viewing this content are expected to read the full disclaimer in our website.
